Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daiichi Sankyo Company ( (JP:4568) ) has issued an update.
Daiichi Sankyo has disclosed the progress of its ongoing share buyback program, reporting the acquisition of 3,403,600 of its own ordinary shares on the Tokyo Stock Exchange between January 1 and January 31, 2026, at a total cost of approximately JPY 10.0 billion. This transaction forms part of a larger board-approved repurchase framework authorized in April 2025, which allows for the buyback of up to 80 million shares or JPY 200 billion through March 24, 2026; as of the end of January 2026, the company has utilized only a small portion of that capacity, signaling continued scope for further capital return and potential support of its share price and capital structure optimization over the remaining program period.
The most recent analyst rating on (JP:4568) stock is a Hold with a Yen2964.00 price target. To see the full list of analyst forecasts on Daiichi Sankyo Company stock, see the JP:4568 Stock Forecast page.
More about Daiichi Sankyo Company
Daiichi Sankyo Company, Limited is a Japan-based pharmaceutical group listed on the Prime Market of the Tokyo Stock Exchange, focusing on the research, development and commercialization of prescription medicines and related healthcare products for global markets.
YTD Price Performance: -15.29%
Average Trading Volume: 7,867,098
Technical Sentiment Signal: Sell
Current Market Cap: Yen5286.4B
See more insights into 4568 stock on TipRanks’ Stock Analysis page.